Compared with GLP-1 RA treatment, tirzepatide treatment was associated with greater reductions in HbA1c (treatment difference, −0.34 percentage points; 95% CI, −0.44 to −0.24 percentage points) and body weight (treatment difference, −2.9 kg; 95% CI, −4.8 to −1.1 kg) over 20 months. The gene discussed is GCG; the disease is rheumatoid arthritis.